Merck Sells Generics Business to Mylan for EUR 4.9 Billion
Merck KGaA announced that it will sell its Generics business to Mylan Laboratories Inc, Canonsburg, PA USA. Merck and Mylan have signed a share purchase agreement whereby Mylan will acquire all Merck Generics companies throughout the world for EUR 4.9 billion.
The divested Generics business represents EUR 1,802 million of sales in 2006. The agreement is subject to regulatory approval. Closing of the transaction is expected in the second half of 2007.
In 2006, Merck's Generics division accounted for 29% of Merck Group sales and 28% of the Group's operating result. Generics sales in 2006 rose 6.9% to EUR 1,819 million while the operating result rose 29% to EUR 307 million. Merck Generics, which has nearly 5,000 employees, sells products in more than 90 countries and maintains a global network of production and marketing operations.
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.